carmofur has been researched along with Ovarian Neoplasms in 7 studies
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " HCFU might be effective against gynecologic cancers when used in maintenance therapy at a lower dosage (300--400 mg) than previously estimated." | 1.27 | Concentrations of a new antitumor agent, 1-hexylcarbamoyl-5-fluorouracil in serum and gynecologic tumor tissue. ( Matsui, Y; Okudaira, Y; Sawada, M, 1983) |
| "Furthermore, the 5-FU level in ovarian cancer tissues was much higher than that in the tissues of the contralateral normal ovary, suggesting that degradation of 5-FU might be delayed in cancer tissue." | 1.27 | [Estimation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 5-FU concentrations in sera and resected specimens from patients with ovarian tumors]. ( Iguchi, T; Ino, Y; Isono, T; Sato, M; Takeda, Y; Takizawa, K; Yokoo, I, 1988) |
| " Even so, HCFU should be dosed when needed in spite of this risk." | 1.27 | [A case of leukoencephalopathy caused by HCFU]. ( Abe, S; Kamata, H; Kisida, S; Miyagawa, N; Murakami, A; Nagano, H; Ueda, K; Yasui, H, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noda, T | 1 |
| Kosakai, H | 1 |
| Tsujimura, K | 1 |
| Nakanishi, A | 1 |
| Shintani, M | 1 |
| Kamamoto, Y | 1 |
| Shimamoto, I | 1 |
| Ichijo, M | 1 |
| Sawada, M | 3 |
| Matsui, Y | 1 |
| Okudaira, Y | 1 |
| Sipilä, P | 1 |
| Kivinen, S | 1 |
| Gröhn, P | 1 |
| Vesala, J | 1 |
| Heinonen, E | 1 |
| Takizawa, K | 1 |
| Ino, Y | 1 |
| Isono, T | 1 |
| Sato, M | 1 |
| Yokoo, I | 1 |
| Iguchi, T | 1 |
| Takeda, Y | 1 |
| Kamata, H | 1 |
| Murakami, A | 1 |
| Miyagawa, N | 1 |
| Yasui, H | 1 |
| Nagano, H | 1 |
| Abe, S | 1 |
| Ueda, K | 1 |
| Kisida, S | 1 |
| Ozaki, M | 1 |
| Hongo, J | 1 |
| Hirota, Y | 1 |
| Inagaki, M | 1 |
1 trial available for carmofur and Ovarian Neoplasms
| Article | Year |
|---|---|
[Clinical trial of carmofur (HCFU) in the treatment of malignant ovarian cancer--The first report: combination therapy with endoxan, mitomycin C, and toyomycin].
Topics: Adult; Aged; Antineoplastic Agents; Chromomycin A3; Clinical Trials as Topic; Cyclophosphamide; Drug | 1983 |
6 other studies available for carmofur and Ovarian Neoplasms
| Article | Year |
|---|---|
Concentrations of a new antitumor agent, 1-hexylcarbamoyl-5-fluorouracil in serum and gynecologic tumor tissue.
Topics: Antineoplastic Agents; Female; Fluorouracil; Humans; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1983 |
Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma.
Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carc | 1989 |
[Experimental chemotherapy of ovarian cancers heterotransplanted in nude mice].
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1985 |
[Estimation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 5-FU concentrations in sera and resected specimens from patients with ovarian tumors].
Topics: Administration, Oral; Female; Fluorouracil; Humans; Ovarian Neoplasms; Ovariectomy; Ovary; Uterus | 1988 |
[A case of leukoencephalopathy caused by HCFU].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; B | 1988 |
[Effect of post operative maintenance chemotherapy against ovarian cancer].
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Humans; Mice; Mice, | 1987 |